Neha Patil (Editor)

Recipharm

Updated on
Edit
Like
Comment
Share on FacebookTweet on TwitterShare on LinkedInShare on Reddit
Type
  
Private

Headquarters
  
Sweden

Number of employees
  
1,204

Net income
  
SEK 46 million (2008)

Founded
  
1995

Recipharm httpswwwrecipharmcomthemescustomrecirecip

Industry
  
Pharmaceutical Contract Development and Manufacturing Organisation

Key people
  
Lars Backsell, Chairman Thomas Eldered, CEO

Products
  
Pharmaceutical products for humans

Revenue
  
SEK 1,423 million (2008)

Stock price
  
RECI-B (STO) SEK 120.50 -0.25 (-0.21%)24 Mar, 5:29 PM GMT+1 - Disclaimer

Subsidiaries
  
Recipharm Strangnas Ab

Profiles

LinkedIn

Torkel gren recipharm ab metal coordinated pharmaceuticals


Recipharm AB is a Swedish company, active as a pharmaceutical contract development and manufacturing organization(CDMO), with production facilities in Sweden, France, the UK and Switzerland and a development site in Sweden. Recipharm employs over 1400 people and operates nine production facilities. Its current production consists of over six hundred different products in a variety of dosage forms to global pharmaceutical companies. Recipharm was listed on the Stockholm Stock Exchange in April 2014.

Contents

Recipharm ab sweden received the esqr s international diamond prize 2015 in vienna


History

  • 1995 - The company Recip was founded, by the owners Lars Backsell and Thomas Eldered, after a Management Buyout of a tablet production site owned by Pharmacia. Recip at this stage had 140 employees an 220 million SEK turnover.
  • 1998 - Recip’s first CMO commissions for two major Nordic pharmaceutical companies. Tricum Fibres site in Höganäs, Sweden, was acquired.
  • 2001 - The CMO brand Recipharm was established.
  • 2002 - A penicillin plant in Strängnäs, Sweden, was acquired from AstraZeneca.
  • 2004 - A semi solid facility in Karlskoga, Sweden, was acquired from AstraZeneca.
  • 2005 - The organisation was restructured into separate subsidiaries.
  • 2007 - A final decision was made, to focus only on outsourcing business. The distribution company with the Recip products was sold to Meda. A sterile facility was acquired in Monts, Indre-et-Loire, France, from AstraZeneca. A new development centre was obtained. A “multi-purpose” facility was acquired in Great Britain.
  • 2008 - Acquisition of: Lyophilisation facility in Switzerland, A capsule production facility in Fontaine-lès-Dijon, France, The majority share of an AstraZeneca biotech laboratory in Södertälje, Sweden. About 1400 employees, turnover 1427 million SEK. The name of the company was changed from Recip to Recipharm.
  • 2014 - In August, the company announced its acquisition of Corvette Pharmaceutical Services for $159 million and in November the company announced it would acquire Lusomedicamenta for $140 million.
  • 2015 – In October the company acquired Nitin Lifesciences for $103 million.
  • 2016 – In February the company acquired Mitim for $75.5 million (SEK640 million)

    • References

    Recipharm Wikipedia
    (Text) CC BY-SA